本文件适用于使用动物源性材料制造的非体外诊断性医疗器械，这些医疗器械不可行或已被证明不可行。它与ISO 14971一起规定了一个程序，以识别与此类设备相关的危害和危险情况，估计和评估由此产生的风险，控制这些风险，并监测控制的有效性。此外，它概述了剩余风险可接受性的决策过程，考虑到ISO 14971中定义的剩余风险的平衡，以及与可用替代品相比的预期医疗效益。本文件旨在提供与使用动物组织或衍生物制造的医疗器械的典型危害相关的风险管理要求和指导，例如: a） 细菌、霉菌或酵母菌污染； b） 病毒污染； c） 导致传染性海绵状脑病（TSE）的病原体污染； d） 引起不期望的热原、免疫或毒理学反应的材料。 对于寄生虫和其他未分类的致病实体，类似的原则也适用。 本文件未规定可接受性水平，因为可接受性水平由多种因素决定，因此此类国际标准中无法规定可接受性水平，但附录C中提到的某些特定衍生物除外。附录C规定了牛脂衍生物、动物炭、牛奶和牛奶衍生物、羊毛衍生物和氨基酸的TSE风险可接受性水平。 本文件未规定医疗器械生产所有阶段的质量管理体系。 本文件不包括人体组织在医疗设备中的应用。 注1:本文件不要求在制造过程中建立完整的质量管理体系。然而，需要注意控制医疗器械生产或再加工所有阶段的质量管理体系国际标准（见ISO 13485）。 注2:关于本文件的应用指南，见附件A。

This document applies to medical devices other than in vitro diagnostic medical devices manufactured utilizing materials of animal origin, which are non-viable or have been rendered non-viable. It specifies, in conjunction with ISO 14971, a procedure to identify the hazards and hazardous situations associated with such devices, to estimate and evaluate the resulting risks, to control these risks, and to monitor the effectiveness of that control. Furthermore, it outlines the decision process for the residual risk acceptability, taking into account the balance of residual risk, as defined in ISO 14971, and expected medical benefit as compared to available alternatives. This document is intended to provide requirements and guidance on risk management related to the hazards typical of medical devices manufactured utilizing animal tissues or derivatives such as: a) contamination by bacteria, moulds or yeasts; b) contamination by viruses; c) contamination by agents causing transmissible spongiform encephalopathies (TSE); d) material responsible for undesired pyrogenic, immunological or toxicological reactions. For parasites and other unclassified pathogenic entities, similar principles can apply. This document does not stipulate levels of acceptability which, because they are determined by a multiplicity of factors, cannot be set down in such an international standard except for some particular derivatives mentioned in Annex C. Annex C stipulates levels of TSE risk acceptability for tallow derivatives, animal charcoal, milk and milk derivatives, wool derivatives and amino acids. This document does not specify a quality management system for the control of all stages of production of medical devices. This document does not cover the utilization of human tissues in medical devices. NOTE 1 It is not a requirement of this document to have a full quality management system during manufacture. However, attention is drawn to international standards for quality management systems (see ISO 13485) that control all stages of production or reprocessing of medical devices. NOTE 2 For guidance on the application of this document, see Annex A.